Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine if Caduet will lower blood pressure to <140/90 mmHg and lower LDL Cholesterol to <100 mg/dL in subjects with hypertension and dyslipidemia who are not currently being treated for these medical conditions.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Caduet | Drug |
| Measure | Description | Time Frame |
|---|---|---|
| The percentage of subjects achieving both blood pressure goal (<140/90 mmHg) and LDL-C goal (<100 mg/dL) at Week 4. |
| Measure | Description | Time Frame |
|---|---|---|
| The percentage of subjects achieving both blood pressure goal (<140/90 mmHg) and LDL-C goal (<100 mg/dL) at Week 8. | ||
| Change from Baseline to Week 4 in SBP, DBP, and Framingham 10-year CHD risk score. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pfizer Investigational Site | Jonesboro | Arkansas | 72401 | United States | ||
| Pfizer Investigational Site |
Not provided
| Label | URL |
|---|---|
| To obtain contact information for a study center near you, click here. | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Percent change from Baseline to Week 4 in LDL-C, HDL, TC, and TG. |
| The percentage of study subjects achieving each of the following goals at Week 4: SBP, DBP, and LDL-C. |
| Change from Baseline to Week 8 in SBP, DBP, and Framingham 10-year CHD risk score. |
| Percent change from Baseline to Week 8 in LDL-C, HDL, TC, and TG. |
| The percentage of study subjects achieving each of SBP, DBP, and LDL-C goals at Week 8. |
| Little Rock |
| Arkansas |
| 72204 |
| United States |
| Pfizer Investigational Site | Garden Grove | California | 92843 | United States |
| Pfizer Investigational Site | Long Beach | California | 90806 | United States |
| Pfizer Investigational Site | Tustin | California | 92780 | United States |
| Pfizer Investigational Site | Aventura | Florida | 33180 | United States |
| Pfizer Investigational Site | Fort Lauderdale | Florida | 33308 | United States |
| Pfizer Investigational Site | Miami | Florida | 33137 | United States |
| Pfizer Investigational Site | Pembroke Pines | Florida | 33027 | United States |
| Pfizer Investigational Site | Atlanta | Georgia | 30309 | United States |
| Pfizer Investigational Site | Decatur | Georgia | 30033 | United States |
| Pfizer Investigational Site | Bossier City | Louisiana | 71111 | United States |
| Pfizer Investigational Site | Fair Haven | Michigan | 48023 | United States |
| Pfizer Investigational Site | Livonia | Michigan | 48152 | United States |
| Pfizer Investigational Site | Jackson | Mississippi | 39201 | United States |
| Pfizer Investigational Site | Jackson | Mississippi | 39202 | United States |
| Pfizer Investigational Site | Excelsior Springs | Missouri | 64024 | United States |
| Pfizer Investigational Site | Berlin | New Jersey | 08009 | United States |
| Pfizer Investigational Site | Elizabeth | New Jersey | 07202 | United States |
| Pfizer Investigational Site | Princeton | New Jersey | 08540 | United States |
| Pfizer Investigational Site | South Bound Brook | New Jersey | 08880 | United States |
| Pfizer Investigational Site | Binghamton | New York | 13901 | United States |
| Pfizer Investigational Site | Monroe | North Carolina | 28112 | United States |
| Pfizer Investigational Site | Winston-Salem | North Carolina | 27103 | United States |
| Pfizer Investigational Site | Cincinnati | Ohio | 45236 | United States |
| Pfizer Investigational Site | Dayton | Ohio | 45406-5144 | United States |
| Pfizer Investigational Site | Eugene | Oregon | 97404 | United States |
| Pfizer Investigational Site | Bensalem | Pennsylvania | 19020 | United States |
| Pfizer Investigational Site | Kingsport | Tennessee | 37660 | United States |
| Pfizer Investigational Site | Beaumont | Texas | 77702 | United States |
| Pfizer Investigational Site | Colleyville | Texas | 76034 | United States |
| Pfizer Investigational Site | Houston | Texas | 77030 | United States |
| Pfizer Investigational Site | Temple | Texas | 76502 | United States |
| Pfizer Investigational Site | Norfolk | Virginia | 23510 | United States |
| ID | Term |
|---|---|
| D006973 | Hypertension |
| D050171 | Dyslipidemias |
| ID | Term |
|---|---|
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D052439 | Lipid Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C487936 | amlodipine, atorvastatin drug combination |
Not provided
Not provided
Not provided